The prospects of prolonged organ xenograft function by Starzl, TE
THE PROSPECTS OF PROLONGED 
ORGAN XENOGRAFT FUNCTION 
Thomas E. Starzl, M.D., Ph.D. 
From the Transplantation Institute, and Department of Surgery, 
University of Pittsburgh Medical Center and the Veterans 
Administration Medical Center, Pittsburgh, Pennsylvania. 
Supported by Research Grants from the Veterans Administration and 
Project Grant No. DK 29961 from the National Institutes of 
Health, Bethesda, Maryland. 
Reprint Address: Thomas E. Starzl, M.D., Ph.D. Department of 
Surgery, 3601 Fifth Avenue, University of Pittsburgh, Pittsburgh, 
Pennsylvania, 15213. 
Clinical xenotransplantation is the diamond inside the 
protective humoral immunity shell that has been so hard to crack. 
How difficult is it going to be to shape the diamond if we break 
through to it? We do not know for discordant species 
combinations because it has been impossible to breach the humoral 
barrier and find out. However, we do have information about 
concordant combinations such as hamster to rat and chimpanzee and 
baboon to human. 
GRAFT ACCEPTANCE: A NEW PERSPECTIVE 
What happens when organ allografts or xenografts survive 
chronically is shown in Figure 1. Passenger leukocytes which 
originally come to the organs from the bone marrow promptly 
migrate throughout the recipient and survive after 
transplantation (donor cell chimerism) and are replaced in the 
graft with a reverse traffic of recipient leukocytes. With 
success, the coexisting immunocyte populations induce non-
reactivity, each to the other (1). 
The recent discoveries leading to this realization have been 
a scientific epiphany. The dominant event in the resulting 2-way 
immune reaction of organ transplantation is of course the host 
versus graft reaction (rejection) which gathers force at first, 
but then wanes in successful cases. The graft versus host 
reaction mounted by the smaller passenger leukocyte population is 
not clinically detectable unless it causes graft vs host disease 
but it goes through the same waxing and waning transition. This 
component can be safely augmented by infusing bone marrow cells 
from the organ donor as shown in Figure 1 for the heart providing 
the recipient is not cytoablated. The reason is that the 
coexisting immune reactions are partially cancelling by gradually 
inducing non-reactivity, each to the other, in various stages of 
peripheral tolerance. 
The reciprocal influence of the 2 cell populations also 
explains why HLA (tissue) matching is so poorly predictive of 
outcome (2). With a severe tissue misma.tch, the genetically 
determined strong rejection is mitigated by the GVH. Thus, there 
is an escalating bidirectional immune reaction with successively 
greater mismatches. Yet, the clinical success rate with 
allografts is surprisingly similar throughout the whole spectrum 
of histocompatibility, being reliably increased in actual 
experience only when there is a perfect match. There is 
considerable evidence that the same events must occur for human 
acceptance of an animal organ. 
INFECTIOUS DISEASE IMPLICATIONS 
OF XENOTRANSPLANTATION 
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The spectacular infectivity of infested organs is easy to 
understand in the context of the foregoing migratory phenomena. 
The missionary donor white cells travel to every part of the 
recipient body, to which they may carry viruses. This is not a 
reason for hand wringing. Donor screening and postoperative 
infectious disease monitoring have been the empirical solutions 
to such problems throughout the whole history of conventional 
allotransplantation. The same will be true for 
xenotransplantation. 
THE ROLE OF IMMUNOSUPPRESSION 
For the desired outcome from these donor-recipient cellular 
interactions, an umbrella of immunosuppression is necessary 
(Figure 1), probably for life in some recipients. However, there 
are numerous examples of successful drug discontinuance in 
patients and animals (I), even in recipients of xenografts. Two 
years ago in London, Ontario, David Grant and Cal Stiller 
transplanted the liver of a baboon to a rhesus monkey with a 
modification of the treatment strategy developed by Murase et al 
(3) in the laboratory and used for our 2 recent baboon to human 
liver transplantations (see below). One year ago, all 
immunosuppression was stopped. The still healthy chimeric rhesus 
monkey is proof of the feasibility of xenotransplantation in 
subhuman primates. There are other examples of long xenograft 




and Oklahoma City), but the lasting xenograft tolerance in the 
Canadian experiment has been a unique achievement thus far. 
Thus, the drugs that we use in the transplantation clinics 
or laboratories are only handmaidens that permit or encourage the 
expression of a normal response capability of both the 
interacting donor and recipient immune systems. The orchestra 
leader in the symphony of graft acceptance is the dendritic cell 
(4), the antigen presenting leukocyte discovered by Steinman and 
Cohn at Rockefeller University in 1973 (5) 
The treatment used for the 2 Pittsburgh liver 
xenotransplantations (6,7) consisted of a four-drug cocktail: FK 
506 (now tacrolimus) given intravenously or orally, 
cyclophosphamide intravenously and orally, prednisone, and 
prostaglandin E1. The striking synergism of cyclophosphamide and 
FK 506 had been demonstrated in experiments in hamster to rat 
heart and liver xenotransplantation (3). Untreated rat 
recipients of hamster livers survive for 7 days before being 
destroyed by combined cellular and humoral rej ection. This 
survival is increased to 35 days with the T-cell directed FK 506 
given alone. In contrast, survival is prolonged only slightly 
using monotherapy with cyclophosphamide or other antimetabolites 
such as brequinar or mycophenolate mofetil which suppress B-cell 
antibody responses. However, FK 506 combined with a short course 
4 
of any of the three anti-metabolite drugs gave uniform 100 day 
survival after hamster to rat liver or heart xenotransplantation. 
The animals were proven to be chimeric. 
the T-cell directed FK 506 and 
Thus, the combination of 
the B-cell suppressing 
antimetabolites was the linchpin of the clinical protocol to 
which the prednisone and perioperative prostaglandin were added. 
THE PITTSBURGH LIVER XENOTRANSPLANTATIONS 
The first patient had the best course (6). He became 
jaundice free for most of the 70 days of his survival. However, 
his canalicular enzymes were increased from the second week 
onward to a peak alkaline phosphatase of over 10,000 IU, 
suggesting biliary obstruction. Serum transaminases, an 
indicator of liver cell injury, were not greatly elevated at any 
time. At autopsy at 70 days, the entire biliary tree was plugged 
by inspisated bile and most of the intrahepatic ducts were 
denuded of epithelium. The findings were essentially the same in 
the second case. In addition, both recipients died of infection 
and both developed renal failure. Most importantly, neither 
achieved normal liver function. 
The failure in the 2 cases was not explained by either 
vascular or cellular rej ection. Only one of the 7 biopsies 
obtained from Patient 1 (this on day 12) had evidence of cellular 
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rejection by conventional criteria, and this was mild and focal. 
On day 64 after several hypotensive episodes, there was some 
centrilobular hepatocyte drop out. No definite evidence of 
cellular rejection was seen in any of the 7 biopsy samples taken 
from Patient 2 over a 26 day period. These benign findings were 
in striking contrast to the fierce cellular rejection found in 6 
baboon kidney grafts 6 to 60 days after renal xenotransplantation 
under azathioprine and prednisone in 1963 and early 1964 (8). 
The recent liver xenografts also were entirely free of the 
arteritis that had been seen in all previous baboon to human 
kidney or heart grafts. There was no trace of the occlusive 
endotheliolitis that appeared to be responsible for patchy 
gangrene of the 1963 kidney xenografts and in the baboon heart of 
Bailey's Baby Fae case (9). In these cases, the necrotic tissue 
was interspersed between islands of still functional parenchyma. 
In contrast, the transplanted baboon livers appeared grossly 
normal at surgical re-exploration shortly before death at 70 and 
26 days. 
The livers, which were too small for their human recipients, 
regenerated up to an appropriate larger size within 2 - 3 weeks. 
Finally, widespread chimerism was demonstrated with polymerase 
chain reaction (peR) studies of tissues retrieved at autopsy 70 
and 26 days after operation. 
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With so many favorable findings, why were these efforts 
unsuccessful? Extensi ve analyses and interpretations have been 
published elsewhere (6,7) In both cases, the conventional 
lymphocytotoxic crossmatch of the recipient sera with their donor 
lymphocytes was positive initially but negative after 
dithiothreitol treatment, meaning that the preformed antibodies 
were largely IgM. The conventional crossmatches became negative 
postoperatively. One hour after revascularization, sludging as 
well as the presence of a few polymorphonuclear leukocytes was 
seen in the sinusoids of the xenografts. 
Both the sludging and the appearance of polys were 
compatible with the diagnosis of an aborted hyperacute rejection. 
Complement studies were consistent with this possibility. Total 
complement was depleted for almost 2 weeks while complement 
components C3, 4, and 5 became undetectable. During this time, 
circulating immune complexes appeared. These complement changes 
were similar to those in recipients of allografts which escaped 
hyperacute rejection despite transplantation across a positive 
lymphocytotoxic crossmatch (discussed in 7) . 
Although the biopsies were thought to be normal at first 
examination, closer inspection showed a very fine microsteatosis 
in the hepatocytes of both xenografts which became progressively 
more obvious in the second case over the next few days. 
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Microsteatosis also has been reported in cases of human to human 
liver transplantation carried out in the presence of positive 
cytotoxic crossmatch and in cases in which hepatic allografts 
have had inexplicable primary non-function. IgM and IgG binding 
was found in the baboon xenografts. The IgM largely disappeared 
from the graft tissues by 24 days but significant amounts of IgG 
remained. 
CONCLUSION FROM BABOON CLINICAL TRIALS 
The evidence was that our 2 patients had encountered a slow 
motion version of the hyperacute rejection described earlier this 
morning by Dr. Platt. This sobering conclusion prompted us to 
cancel the last 2 cases of our IRB-approved series of 4 (7). We 
have no clinical protocols current or pending. Instead, we are 
exploring strategies in the laboratory to deal with the problem 
of subtle complement activation, whether antibody initiated 
(classical pathway) or not (alternative pathway). As discussed 
elsewhere (7) , this special kind of rej ection was first 
recognized in both allograft and xenograft recipients more than 
30 years ago. The problem was thus a familiar one for which a 
satisfactory solution had not been found (i.e. in highly 













the use of 
concordant donor species was not going to be possible without 
resolving the historically intractable problem of humoral 
rejection. Fine tuning of available agents might permit 
occasional success in humans with the baboon donor, but the field 
(including the use of distant species such as the pig) would be 
frozen without some therapeutic ingredient which either was not 
available or had not been tried. 
REGULATORY ISSUES 
A policy conference was convened on June 25-27, 1995, to 
determine, first, if and secondarily, how, to foster, apply, and 
regulate xenotransplantation technology. It seems to me that the 
only immediate question is whether to foster these efforts. The 
doomsday arguments voiced by some of the participants about 
creating new infectious disease syndromes with clinical trials 
might have been credible a third of a century ago. Such concerns 
largely have been defused by the return of tens of thousands of 
immunosuppressed organ recipients to their pets, farms, homes, 
heal th care professions, ministries, public office, and other 
ways of life. The patients did not prove to be walking time 
bombs who introduced or spread HIV, the Ebola epidemic, or the 
Marburg virus. I know of no single such example in the now huge 
transplant recipient population. A decision whether to foster 
xenotransplant developments should not hinge on the possibility 
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of causing a modern day plague. From what we have learned at a 
practical level, that risk, while undeniable, is miniscule. 
We are discussing here an ethical subject which concerns the 
relationship of humans to animals at spiritual and other levels. 
Therefore, the probity of xenotransplantation or the lack of it 
is an issue for all of society to decide, not any small outspoken 
fraction of it or even the medical profession. I might add here 
that I respect and take seriously those who are opposed to 
research and development in xenotransplantation. Scientists and 
physicians or surgeons like me tend to be lined up on the other 
side. We also are a small and noisy group. We cannot forget 
that we are the servants, not the masters, of those who need our 
medical services, or someday might. Thus, we need a signal from 
the public at large about desisting in these efforts, or 
proceeding. 
As for application and regulation, there is nothing in my 
opinion to apply at a practical level or to regulate now, or in 
the near future. The science simply is not that far advanced. 
Regulating something that does not exist is the best way I know 
to ensure that it never will exist. Governance of the very 
limited clinical research that is justified at the present time 
should not be burdenseom for for the legislatively mandated IRB's 
at a local level. This established framework should be 
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buttressed by the formation of national resource groups which can 
provide expertise and guidelines. No case should ever be done 
without open disclosure, a condition that will necessitate 
registration of all xenotransplant cases. 
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REFERENCES 
1. Starzl TE, Demetris AJ, Trucco M, Murase N, Ricordi C, 
Ildstad 5, Ramos H, Todo 5, Tzakis A, Fung JJ, Nalesnik M, Zeevi 
A, Rudert WA, Kocova M: Cell migration and chimerism after 
whole-organ transplantation: The basis of graft acceptance. 
Hepatology 17:1127-1152, 1993. 
2. Starzl TE, Rao AS, Trucco M, Fontes P, Fung JJ, Demetris AJ: 
Explanation for loss of the HLA matching effect. Transplant Proc 
27:57-60, 1995. 
3. Murase N, Starzl TE, Demetris AJ, Valdivia L, Tanabe M, 
Cramer D, Makowka L: Hamster-to-rat heart and liver 
xenotransplantation with FK506 plus antiproliferative drugs. 
Transplantation 55:701-708, 1993. 
4. Lu L, Rudert WA, Qian S, McCaslin D, Fu F, Rao AS, Trucco M, 
Fung JJ, Starzl TE, Thomson AW: Growth of donor-dervived 
dendritic cells from the bone marrow of murine liver allograft 
recipients in response to granulocyte/macrophage colony-
stimulating factor. J Exp Med 27:191-193, 1995. 
5. Steinman RM, Cohn ZA: Identification of a novel cell type in 
peripheral lymphoid organs of mice. I. Morphology, 
quantitation, tissue distribution. J Exp Med 137:1142, 1973. 
6. Starzl TE, Fung J, Tzakis A, Todo S, Demetris AJ, Marino IR, 
Doyle H, Zeevi A, Warty V, Michaels M, Kusne S, Rudert WA, Trucco 
M: Baboon-to-human liver transplantation. 
1993. 
Lancet 341:65-71, 
7. Starzl TE, Valdivia LA, Murase N, Demetris AJ, Fontes P, Rao 
AS, Manez R, Marino I, Todo S, Thomson AW, Fung JJ: The biologic 
basis of and strategies for clinical xenotransplantation. 
Immunological Rev 141:213-244, 1994. 
8. Starzl TE, Marchioro TL, Peters GN, Kirkpatrick CH, Wilson 
WEC, Porter KA, Rifkind D, Ogden DA, Hitchcock CR, Waddell WR: 
Renal heterotransplantation from baboon to man: 
6 cases. Transplantation 2:752-776, 1964. 
Experience with 
9. Bailey L, Nehlsen-Cannarella S I Concepcion W, Jolley W: 
Baboon to human cardiac xenotransplantation in a neonate. JAMA 
254: 3321-3329, 1985. 
FIGURE LEGEND 
Figure 1 Two-way paradigm (organ). Bidirectional 
mechanism of whole organ graft acceptance involving a graft-vs-
host (GVH) reaction by the bone marrow-derived donor leukocytes 
in the graft that are pitted against the whole recipient 
immunologic apparatus (host-vs-graft [HVG1, rejection). For 
standard whole organ clinical transplantation, the recipient is 
not preconditioned. These principles of allograft acceptance 
apply to xenotransplantation. 
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